Abstract
Rezum therapy is in emerging minimally invasive treatment for BPH. Complications of Rezum are underreported in the literature. We report a case of a 61-year-old male patient who presented to ED two months after Rezum with hematuria and clot retention. US showed prostate size of 315 g with cystic changes. The patient was managed with TURP and unexpectedly showed big contained hematoma below the bladder neck which was evacuated with adequate hemostasis.
In summary, this is the first case of intraprostatic hematoma following Rezum in the literature. Urologists are encouraged to report the adverse effects to build overall possibilities of outcomes or complications in the literature and help to predict and manage adverse effects of such an emerging therapy.